Improving Function, Quality of Life, Glycemia in Diabetics With Dementia

Sponsor

University of Nebraska (Other)

Overall Status

Withdrawn

CT.gov ID

NCT00792662

Collaborator

Alzheimer's Association (Other)

Enrollment

Locations

Arms

Actual Duration (Months)

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary purpose of this study is to determine if the study medication Methylphenidate (Ritalin) will improve subject's blood-sugar control by improving their motivation more than placebo. The secondary objectives of the study are to determine if daily functioning and quality of life improves with methylphenidate treatment.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus Alzheimer's Disease Apathy Dementia	Drug: Methylphenidate Drug: Placebo	Phase 4

Detailed Description

A total of 50 subjects will be enrolled in this study. This study is being conducted at two sites, UNMC and the Omaha VA Medical Center.

The subject will be asked to take the study drug in the form of a capsule to be taken twice daily. Whether the subject receives methylphenidate or placebo (a pill that has a similar appearance to the study drug, but has no medicine) will be determined by random chance. The probability that the subject will receive methylphenidate is 1 in every 2 subjects or 50% of the time. Subjects receiving methylphenidate will be starting at 5 milligrams (mg) twice daily. Dosage will then be increased to 10mg twice daily at 2 weeks.

After the initial visits, the subjects will be asked to come for follow-up every month for the next 4 visits (sixteen weeks total). During each visit subjects will again be asked questions to assess their motivation, memory, functional status and quality of life. Blood will be drawn and an electrocardiogram (ecg/ekg) will be taken to assess the patient's safety twice during the study.

Partial Compensation may be available for participation.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Improving Function, Quality of Life, Glycemia in Diabetics With Dementia

Actual Study Start Date :

Nov 1, 2008

Actual Primary Completion Date :

Dec 1, 2011

Actual Study Completion Date :

Dec 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Methylphenidate Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.	Drug: Methylphenidate Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study. Other Names: Ritalin
Placebo Comparator: Placebo Standard inactive pill.	Drug: Placebo Standard inactive pill. Other Names: Sugar Pill

Arm

Intervention/Treatment

Experimental: Methylphenidate

Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.

Drug: Methylphenidate

Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.

Other Names:

Ritalin

Placebo Comparator: Placebo

Standard inactive pill.

Drug: Placebo

Standard inactive pill.

Other Names:

Sugar Pill

Outcome Measures

Primary Outcome Measures

Hemoglobin A1C (HbA1c) will be used as marker for glycemic control. It is accepted as the best marker for glycemic control in the previous 120 days. Changes in HbA1c are clinically meaningful. [16 weeks]

Secondary Outcome Measures

Apathy Evaluation Scale-Clinician (AES-C): The clinician-rated version will be used for this project. This 18 item scale with scores ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. [16 weeks]
Clinical Global Impression (CGI): This is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. [16 weeks]
Instrumental Activities of Daily Living (IADL): It is a survey assessing eight domains of higher functions necessary to live independently. It is rated from 0-23 based on the independent living of the patient. [16 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of dementia of the Alzheimer type (Diagnostic and Statistical Manual-IV Text Revision (DSM-IV TR) criteria)
Diagnoses of diabetes mellitus type II
Poor glycemic control (Hemoglobin A1c (HbA1c ≥ 7.0%))
Mild to Moderate Alzheimer's dementia (Mini Mental State Examination (MMSE) >18, but <29)
Apathy Evaluation Scale (AES) score of more than 30
Ability to provide informed consent by either the patient or caregiver.
If subjects are being treated with antidepressants, they should be on a stable dose of antidepressants for at least two months prior to the enrollment into the study.
If subjects are being treated with cholinesterase inhibitors and memantine, they should be on stable dose of those medications at least four months prior to the enrollment into the study.
Subjects should be on stable dose of statins and ACE inhibitors for ≥ 2 months.
Subjects should be on stable dose of diabetes treatment for 2 months prior to enrollment.

Exclusion Criteria:

Severe dementia (MMSE < 18)
Patient currently taking methylphenidate or hypersensitivity or prior significant adverse events with methylphenidate.
Patients currently taking Adderall (amphetamine mixed salts) or Dexedrine (dextroamphetamine sulphate) or any other amphetamine product.
Uncontrolled hypertension (BP > 140/90) or tachycardia (100) at screening visit
Patients with frontotemporal dementia
Patients meeting criteria for Major Depressive Disorder on the Mini International Neuropsychiatric Inventory (MINI)
Patients with active psychosis as determined by MINI
Patients currently being treated with antipsychotics
History of uncontrolled seizure disorder
History of malignant hypertension, symptomatic cardiovascular disease, cardiomyopathy, known structural cardiac defect or medically unstable arrhythmias.
History of Tourette's syndrome or presence of motor tics
Patients with glaucoma
Patients taking monoamine oxidase inhibitors (MAOIs)
Patient taking clonidine
Patients being treated with insulin pump